Gufic Biosciences Limited
NSE: GUFICBIO BSE: GUFICBIO
NSE
349.90
6.25 (1.82%)
Prev Close
343.65
Open Price
341.2
Volume
40,163
Today Low / High
340.1 / 355.15
52 WK Low / High
278 / 504.25
Range
332 - 367
BSE
349.85
4.80 (1.39%)
Prev Close
345.05
Open Price
335.8
Volume
5,141
Today Low / High
335.8 / 354
52 WK Low / High
278 / 501.1
Range
332 - 367
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 349.9 (target range: 332 - 367), reflecting a change of 6.25 (1.81871%). On the BSE, it is listed at 349.85 (target range: 332 - 367), showing a change of 4.8 (1.3911%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
341.20
2.55%
17 Apr
343.80
-0.04%
16 Apr
340.45
0.98%
15 Apr
335.00
1.63%
11 Apr
314.50
4.80%
09 Apr
316.35
-2.07%
08 Apr
313.75
0.83%
07 Apr
316.10
-1.91%
04 Apr
343.00
-4.26%
03 Apr
341.70
0.67%
02 Apr
341.00
-2.54%
01 Apr
336.05
0.71%
28 Mar
332.80
1.05%
27 Mar
340.00
-2.47%
26 Mar
350.00
-3.70%
25 Mar
352.65
-0.64%
24 Mar
340.15
3.41%
Gufic Biosciences Limited Graph
Gufic Biosciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Gufic Biosciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 349.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 349.85 | 353.35 | 318.01 - 388.68 |
| 356.85 | 285.48 - 428.22 | ||
| 360.35 | 252.24 - 468.45 | ||
| Bearish Scenario | 349.85 | 346.35 | 311.72 - 380.99 |
| 342.85 | 274.28 - 411.42 | ||
| 339.35 | 237.55 - 441.16 |
Overview of Gufic Biosciences Limited
ISIN
INE742B01025
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
54,808
Market Cap
35,087,098,650
Last Dividend
0.1
Official Website
IPO Date
2004-10-19
DCF Diff
672.43
DCF
-328
Financial Ratios Every Investor Needs
Stock Dividend of GUFICBIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-09-17 | September 17, 24 | 0.1 | 0.1 | 2024-09-18 | 2024-10-25 | |
| 2023-09-21 | September 21, 23 | 0.1 | 0.1 | 2023-09-21 | 2023-10-29 | |
| 2022-08-24 | August 24, 22 | 0.1 | 0.1 | 2022-08-25 | 2022-09-29 | |
| 2021-09-09 | September 09, 21 | 0.1 | 0.1 | 2021-09-13 | 2021-10-18 | |
| 2020-11-03 | November 03, 20 | 0.05 | 0.05 | 2020-11-04 | 2020-12-11 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 806.67 Cr | 399.29 Cr | 407.37 Cr | 0.5050 | 5.44 Cr | 111.10 Cr | 289.38 Cr | 86.14 Cr | 8.74 | 148.05 Cr | 0.1068 |
| 2023-03-31 | 690.62 Cr | 485.38 Cr | 205.24 Cr | 0.2972 | 5.16 Cr | 14.90 Cr | 115.33 Cr | 79.70 Cr | 8.22 | 137.23 Cr | 0.1154 |
| 2022-03-31 | 779.16 Cr | 422.82 Cr | 356.34 Cr | 0.4573 | 4.43 Cr | 16.43 Cr | 129.10 Cr | 95.84 Cr | 9.89 | 148.49 Cr | 0.1230 |
| 2021-03-31 | 487.70 Cr | 256.51 Cr | 231.19 Cr | 0.4740 | 2.10 Cr | 9.20 Cr | 68.15 Cr | 44.23 Cr | 4.56 | 85.78 Cr | 0.0907 |
| 2020-03-31 | 378.84 Cr | 277.14 Cr | 101.69 Cr | 0.2684 | 2.00 Cr | 7.43 Cr | 38.54 Cr | 22.69 Cr | 2.34 | 57.90 Cr | 0.0599 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1.14 Cr | 1,092.54 Cr | 559.98 Cr | 532.5605 Cr | 332.92 Cr | 331.78 Cr | 200.48 Cr | 474.17 Cr | 3.85 Cr | 0.00 Cr | 1.78 Cr | 372.0489 Cr |
| 2023-03-31 | 28.60 Cr | 861.16 Cr | 513.35 Cr | 347.8082 Cr | 334.19 Cr | 305.59 Cr | 183.46 Cr | 328.48 Cr | 5.36 Cr | 0.00 Cr | -0.18 Cr | 288.2075 Cr |
| 2022-03-31 | 11.61 Cr | 521.40 Cr | 252.28 Cr | 269.1180 Cr | 64.39 Cr | 52.78 Cr | 115.57 Cr | 155.43 Cr | -0.58 Cr | 5.00 Cr | 0.00 Cr | 186.4016 Cr |
| 2021-03-31 | 6.20 Cr | 392.06 Cr | 218.62 Cr | 173.4366 Cr | 61.54 Cr | 55.34 Cr | 94.40 Cr | 118.46 Cr | 2.83 Cr | 5.00 Cr | 0.01 Cr | 163.6624 Cr |
| 2020-03-31 | 4.26 Cr | 407.52 Cr | 278.19 Cr | 129.3231 Cr | 126.37 Cr | 122.11 Cr | 122.46 Cr | 120.48 Cr | 2.99 Cr | 4.75 Cr | 0.01 Cr | 239.7735 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | -7.4571 Cr | -102.3889 Cr | 82.3810 Cr | -120.1516 Cr | -27.4651 Cr | 1.1368 Cr | -112.6945 Cr | 86.1356 Cr | 5.5070 Cr | -0.9720 Cr | -17.0246 Cr |
| 2023-03-31 | -26.5872 Cr | -190.7265 Cr | 234.3076 Cr | -214.1879 Cr | 16.9939 Cr | 28.6019 Cr | -187.6007 Cr | 79.7048 Cr | 250.0924 Cr | -1.0437 Cr | -67.8907 Cr |
| 2022-03-31 | 106.2395 Cr | -94.5891 Cr | -6.2437 Cr | 18.7864 Cr | 5.4067 Cr | 11.6081 Cr | -87.4531 Cr | 95.8401 Cr | 5.8934 Cr | -0.9211 Cr | -21.1623 Cr |
| 2021-03-31 | 87.2509 Cr | -6.6929 Cr | -78.6180 Cr | 74.8515 Cr | 1.9400 Cr | 6.2014 Cr | -12.3994 Cr | 44.2316 Cr | -61.3922 Cr | -0.3629 Cr | 28.0568 Cr |
| 2020-03-31 | 47.1018 Cr | -42.5305 Cr | -4.2063 Cr | 7.2523 Cr | 0.3649 Cr | 4.1838 Cr | -39.8495 Cr | 22.6879 Cr | 12.6403 Cr | -0.4875 Cr | -14.9131 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 207.79 Cr | 94.17 Cr | 113.63 Cr | 0.5468 | 29.31 Cr | 19.31 Cr | 1.93 | 35.79 Cr | 0.0929 |
| 2024-09-30 | 204.18 Cr | 96.13 Cr | 108.05 Cr | 0.5292 | 34.32 Cr | 21.77 Cr | 2.17 | 38.73 Cr | 0.1066 |
| 2024-06-30 | 202.81 Cr | 128.09 Cr | 74.72 Cr | 0.3684 | 31.47 Cr | 20.86 Cr | 2.08 | 37.03 Cr | 0.1028 |
| 2024-03-31 | 201.78 Cr | 130.08 Cr | 71.70 Cr | 0.3553 | 32.31 Cr | 20.05 Cr | 2.23 | 36.88 Cr | 0.0993 |
| 2023-12-31 | 201.78 Cr | 130.08 Cr | 71.70 Cr | 0.3553 | 32.31 Cr | 22.26 Cr | 2.23 | 36.88 Cr | 0.1103 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 5.74 Cr | 13.66 Cr | 19.40 Cr | 0.00 Cr | 186.84 Cr | 578.39 Cr | 506.12 Cr | 1,104.67 Cr | 530.49 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 13.48 Cr | 0.00 Cr | 0.00 Cr | 13.48 Cr | 0.00 Cr | 0.00 Cr | -532.56 Cr |
| 2024-03-31 | 1.14 Cr | 8.87 Cr | 13.48 Cr | 317.59 Cr | 200.48 Cr | 600.48 Cr | 474.17 Cr | 1,092.54 Cr | 559.98 Cr |
| 2023-12-31 | -16.32 Cr | 32.63 Cr | 16.32 Cr | 0.00 Cr | 0.00 Cr | 16.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 4.33 Cr | 11.99 Cr | 16.32 Cr | 265.01 Cr | 192.21 Cr | 511.42 Cr | 422.26 Cr | 969.39 Cr | 578.72 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 20.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 20.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 22.26 Cr | 8.28 Cr | 0.00 Cr | 0.00 Cr | 8.28 Cr | 24.60 Cr | 16.32 Cr | 0.00 Cr | 8.28 Cr |
| 2023-09-30 | 23.21 Cr | 8.59 Cr | 0.00 Cr | 0.00 Cr | 8.59 Cr | 16.32 Cr | 7.72 Cr | 0.00 Cr | 8.59 Cr |
| 2023-06-30 | 20.62 Cr | 8.47 Cr | 0.00 Cr | 0.00 Cr | 8.47 Cr | 37.10 Cr | 28.62 Cr | 0.00 Cr | 8.47 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Chief Financial Officer
Mr. Devkinandan B. Roonghta
Gender: male
Year Born: 1965
Chairman & MD
Mr. Jayesh Pannalal Choksi
Gender: male
Year Born: 1954
Associate Vice President - Sales & Marketing
Mr. Pinak Padhya
Gender: male
Year Born:
President of Operation
Mr. Ashok Laxman Dev
Gender: male
Year Born:
Senior Vice President - Critical Care SBUs, Nepal & Institution
Mr. Shekhar Tarabir Aley
Gender: male
Year Born:
Chief Executive Officer & Whole Time Director
Mr. Pranav Jayesh Choksi
Gender: male
Year Born: 1983
Whole-Time Director
Mr. Pankaj Jayakumar Gandhi
Gender: male
Year Born: 1959
Company Secretary, Compliance Officer & Legal Manager
Ms. Ami Naresh Shah
Gender: female
Year Born:
Chief Operating Officer
Mr. Nagesh Yarrabathina
Gender: male
Year Born:
Head Human Resource Department
Mr. Sunil Desai
Gender: male
Year Born:
FAQs about Gufic Biosciences Limited
Who is the CEO of the company?
The CEO is Mr. Pranav Jayesh Choksi.
What is the current market price of the stock?
The current price is ₹349.90.
What is the 52-week price range?
The range is ₹278-504.25.
What is the market capitalization of the company?
The market capitalization is ₹3,508.71 crores.
What is the dividend yield?
The dividend yield is 0.03%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 42.69.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Gufic Biosciences Limited (ISIN: INE742B01025) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,508.71 crores and an average daily volume of 54,808 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.1.